Report ID: SQMIG35I2287
Report ID:
SQMIG35I2287 |
Region:
Global |
Published Date: October, 2024
Pages:
157
|
Tables:
100 |
Figures:
76
In March 2022, Galderma presented its new clinical data and high patient satisfaction across its portfolio of dermal fillers, collagen bio stimulators, and liquid neuromodulators at AMWC 2022. Galderma presented a range of new scientific data on its portfolio on its hyaluronic acid dermal filler range, its first liquid neuromodulator, and its original collagen biostimulator at the Aesthetic & Anti-Aging Medicine World Congress 2022.
In February 2022, Amneal expanded its injectables portfolio with 4 new products. Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate injection, USP 0.5 mg/5 mL, have received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (US FDA). Dexamethasone and azacitidine are both currently on the FDA drug shortage list, and Atroprine was granted Competitive Generic Therapy (CGT) status by the FDA.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35I2287